Company Filing History:
3 out of 13 
2 out of 24 
2 out of 6 
Years Active: 2008-2017
Title: Danielle Colledge: Innovating in Hepatitis B Research
Introduction:
In the world of biomedical research, Danielle Colledge has made significant contributions, particularly in the field of hepatitis B virus (HBV). With a track record of several patents and collaborations with esteemed organizations, Danielle's work has been crucial in advancing our understanding of HBV variants and developing potential therapeutic solutions. Let's delve into her latest patents, career highlights, and collaborations.
Latest Patents:
Danielle Colledge's recent patents revolve around hepatitis B viral variants with reduced susceptibility to nucleoside analogs and their applications. These variants exhibit decreased sensitivity to particular agents and antibodies, making them challenging to combat.
The inventions described in these patents have multiple applications. Firstly, they aid in the development of assays for detecting viral variants, enabling effective monitoring of anti-viral treatment regimens. Additionally, they have implications for the design of new or modified vaccines targeting HBV variants. Moreover, the viral variants described in the patents can serve as a valuable tool in screening and developing agents to inhibit HBV infection, replication, and release.
Career Highlights:
During her career, Danielle Colledge has worked with esteemed organizations in the biomedical field, including Austin Health and Melbourne Health. Collaborating with renowned researchers and experts, Danielle has honed her expertise in the study of HBV variants and their impact on disease progression.
Collaborations:
Danielle Colledge has had the privilege of collaborating with several notable individuals in her field, including Angeline Ingrid Bartholomeusz and Anna Ayres. These collaborations have cultivated an environment of knowledge-sharing, contributing to their collective contributions in the fight against HBV.
Conclusion:
Danielle Colledge's expertise and dedication to biomedical research, especially in the realm of HBV variants, have yielded several significant patents and notable collaborations. Her innovative work in the development of assays, vaccines, and potential therapeutic agents has the potential to revolutionize the field of hepatitis B research and improve patient outcomes. As Danielle continues to explore new avenues in hepatitis B research, the future holds great promise for fighting this complex viral infection.